ASTRA Therapeutics

About ASTRA Therapeutics

ASTRA Therapeutics is focused on redefining parasite drug development by leveraging precision-engineered solutions. Their mission is to lead the fight against parasitic diseases using their proprietary Parabulins(r) technology, which targets parasite microtubules selectively while protecting host cells.

Products & Services

Parabulins(r):Tubulin-binding inhibitors that selectively target parasite microtubules, effective against multiple protozoan and worm parasites, offering safer and highly effective treatments for hosts.

ParaX(r) Platform:A revolutionary platform for designing highly selective treatments that target parasite microtubules while safeguarding host cells.

Specialties

Parasitic Disease Treatment Precision Drug Development Microtubule Targeting Anti-Parasitic Small Molecule Drugs

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 7750000 MR: - FA: CHF 7.75 million FAN: 7750000	D: 2025-07-24 FD: 2025-07-24	5 investors

Seed Latest

2025-07-24

$7.8M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Ashwani Sharma

Co-founder & Co-CEO

LinkedIn (Pro only)

N

Natacha Gaillard

Co-Founder & Co-CEO

M

Marshall Ungar

CFO

LinkedIn (Pro only)

A

Arthur Redpath

Animal Health Business Development Leader

V

Valentin Ehrhard

Scientist, Lab Head

View 2 more team members with Pro

Unlock Full Team Directory

Recent News